<DOC>
	<DOCNO>NCT02997189</DOCNO>
	<brief_summary>This multicenter , Phase 2 study ass feasibility , safety efficacy OTO-104 give intratympanic administration subject risk ototoxicity cisplatin chemotherapy regimens treatment cancer .</brief_summary>
	<brief_title>Study OTO-104 Subjects Risk From Cisplatin-Induced Hearing Loss</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Subject age 6 month 21 year inclusive . Subject diagnosed neuroblastoma , hepatoblastoma , osteosarcoma extracranial germ cell tumor previously treat cisplatin carboplatin . Subject schedule receive chemotherapy regimen include cumulative cisplatin dose ≥ 200 mg/m2 . Subject normal baseline auditory function , define ≤ 20 dB 2000 8000 Hz , ears history sensorineural hearing loss . Subject middle ear effusion upon clinical examination . Subject history central nervous system radiotherapy encompass part cochlea receive radiation therapy course study . Subject receive sodiumthiosulfate amifostine therapy chemotherapy . Subject currently participate separate otoprotection clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>